Abstract: Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.
Abstract: The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described.
Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.
Abstract: The present invention provides specific nucleic acid sequences for use in the identification, classification and diagnosis of various sub-types of lung cancers. The present invention permits one to accurately classify lung cancers based on their miR expression profile without further manipulation. Using microRNA microarray data generated from over two hundred formalin-fixed paraffin-embedded (FFPE) resection samples, fine needle aspiration (FNA) samples and fine needle biopsy (FNB) samples of primary lung cancer, microRNA expression profiles were identified that differ significantly for various sub-types of lung cancer.
Abstract: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.
Type:
Application
Filed:
May 19, 2014
Publication date:
September 11, 2014
Applicants:
YEDA RESEARCH AND DEVELOPMENT COMPANY LTD., ROSETTA GENOMICS, LTD.
Abstract: Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.
Abstract: The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy.
Type:
Application
Filed:
January 30, 2014
Publication date:
August 28, 2014
Applicants:
Tel Hashomer Medical Research Infrastructure and Services Ltd., Rosetta Genomics Ltd.
Inventors:
Nitzan ROSENFELD, Yael Spector, Eddie Friedman, Zohar Dotan
Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.
Abstract: The invention provides a method of diagnosing Alzheimer's disease (AD) in a subject by determining the level of expression of one or more miRNAs molecules associated with AD, as well as various nucleic acid molecules relating thereto or derived thereof.
Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
Type:
Application
Filed:
January 30, 2014
Publication date:
July 24, 2014
Applicants:
ROSETTA GENOMICS LTD., REGULUS THERAPEUTICS INC.
Inventors:
C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
Abstract: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.
Type:
Grant
Filed:
February 26, 2008
Date of Patent:
July 1, 2014
Assignees:
Rosetta Genomics Ltd., Yeda Research and Development Company Ltd.
Abstract: Provided herein are isolated viral and human nucleic acids associated with viral infection and various nucleic acid molecules relating thereto or derived therefrom. The nucleic acids may be useful for the prevention, treatment and diagnosis of viral infections.
Type:
Application
Filed:
June 6, 2013
Publication date:
June 26, 2014
Applicant:
ROSETTA GENOMICS, LTD.
Inventors:
Issac Bentwich, Amir Avniel, Ranit Aharonov, Yael Karov, Yonat Shemer-Avni, Asaf Levy
Abstract: The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids.
Type:
Application
Filed:
October 25, 2013
Publication date:
March 27, 2014
Applicants:
Mor Research Applications, Rosetta Genomics Ltd.
Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
Abstract: The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids.
Type:
Grant
Filed:
January 26, 2009
Date of Patent:
November 12, 2013
Assignees:
Rosetta Genomics Ltd., Mor Research Applications
Abstract: The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of specific types of nonsmall-cell lung cancers (NSCLC). The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression pattern of a biological sample.
Type:
Grant
Filed:
August 31, 2009
Date of Patent:
October 22, 2013
Assignee:
Rosetta Genomics Ltd.
Inventors:
Ranit Aharonov, Nitzan Rosenfeld, Shai Rosenwald, Hila Benjamin
Abstract: Provided herein are isolated viral and human nucleic acids associated with viral infection and various nucleic acid molecules relating thereto or derived therefrom. The nucleic acids may be useful for the prevention, treatment and diagnosis of viral infections.
Type:
Grant
Filed:
December 5, 2007
Date of Patent:
July 9, 2013
Assignee:
Rosetta Genomics, Ltd.
Inventors:
Issac Bentwich, Amir Avniel, Ranit Aharonov, Yael Karov, Yonat Shemer-Avni, Asal Levy
Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
Type:
Grant
Filed:
March 10, 2010
Date of Patent:
June 11, 2013
Assignee:
Rosetta Genomics Ltd.
Inventors:
Itzhak Benwich, Amir Avniel, Yael Karov, Ranit Aharonov
Abstract: Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.
Type:
Grant
Filed:
August 4, 2010
Date of Patent:
June 4, 2013
Assignee:
Rosetta Genomics Ltd.
Inventors:
Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
Abstract: Described herein are compositions and methods for the prevention and treatment of hematopoietic malignancies. The compositions are miRNAs and associated nucleic acids.
Type:
Grant
Filed:
January 25, 2008
Date of Patent:
March 5, 2013
Assignees:
Rosetta Genomics, Ltd, Immune Disease Institute